CV Sciences (OTCMKTS:CVSI) Earns Overweight Rating from Analysts at Piper Jaffray Companies

Share on StockTwits

Piper Jaffray Companies began coverage on shares of CV Sciences (OTCMKTS:CVSI) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued an overweight rating and a $5.00 target price on the stock. Piper Jaffray Companies also issued estimates for CV Sciences’ Q3 2019 earnings at $0.01 EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.04) EPS, Q1 2020 earnings at $0.01 EPS, Q2 2020 earnings at $0.02 EPS, Q3 2020 earnings at $0.03 EPS, Q4 2020 earnings at $0.04 EPS and FY2020 earnings at $0.10 EPS.

A number of other equities research analysts have also commented on the company. Roth Capital began coverage on CV Sciences in a research report on Thursday, May 16th. They issued a buy rating and a $9.00 target price on the stock. Zacks Investment Research lowered CV Sciences from a buy rating to a hold rating in a research report on Tuesday, June 18th. Finally, Northland Securities reiterated a buy rating on shares of CV Sciences in a research report on Thursday, May 9th.

Shares of OTCMKTS CVSI opened at $3.20 on Monday. The business’s 50 day moving average price is $3.91 and its 200 day moving average price is $4.72. The firm has a market cap of $317.04 million, a P/E ratio of 35.50 and a beta of -0.50. CV Sciences has a 52 week low of $2.76 and a 52 week high of $9.20. The company has a quick ratio of 2.43, a current ratio of 3.20 and a debt-to-equity ratio of 0.13.

CV Sciences (OTCMKTS:CVSI) last issued its earnings results on Tuesday, August 6th. The company reported $0.01 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.01. The firm had revenue of $16.85 million for the quarter, compared to analyst estimates of $17.45 million. CV Sciences had a negative return on equity of 6.47% and a negative net margin of 3.29%. As a group, research analysts expect that CV Sciences will post -0.04 earnings per share for the current year.

CV Sciences Company Profile

CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Read More: What is the Difference Between Common Shares and Convertible Shares?

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Peabody Energy Co.  to Issue Dividend Increase – $0.15 Per Share
Peabody Energy Co. to Issue Dividend Increase – $0.15 Per Share
Dillard’s  PT Lowered to $37.00 at JPMorgan Chase & Co.
Dillard’s PT Lowered to $37.00 at JPMorgan Chase & Co.
Morgan Stanley Cuts CMS Energy  Price Target to $59.00
Morgan Stanley Cuts CMS Energy Price Target to $59.00
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR  to Sell
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR to Sell
MediciNova  Cut to Strong Sell at BidaskClub
MediciNova Cut to Strong Sell at BidaskClub
Westinghouse Air Brake Technologies  Downgraded by ValuEngine
Westinghouse Air Brake Technologies Downgraded by ValuEngine


 
© 2006-2019 Zolmax.